- Conditions
- Healthy Adult Subjects
- Interventions
- TTYP01, Radicava, Radicava ORS
- Drug
- Lead sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
- Industry
- Eligibility
- 20 Years to 45 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 1,467
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
- Interventions
- Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more
- Conditions
- Healthy, ECG
- Interventions
- CSF-3 watch, designed to monitor a user's heart rate based on ECG (electrocardiogram) and PPG (Photoplethysmograph) readings
- Device
- Lead sponsor
- CardiacSense Ltd.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- CHF10067, Placebo
- Drug · Other
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Dothan, Alabama • St. Petersburg, Florida • Hannibal, Missouri + 3 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab
- Biological · Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more
- Conditions
- Autoimmune Hepatitis
- Interventions
- sPIF, Placebo
- Drug
- Lead sponsor
- Christopher O'Brien, MD
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Miami, Florida • Cherry Hill, New Jersey
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
- Interventions
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
- Procedure · Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Palmoplantar Pustulosis
- Interventions
- Spesolimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Columbia, Missouri • East Windsor, New Jersey + 3 more
- Conditions
- Suicidal Thoughts and Behaviors
- Interventions
- PRECISE
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 26 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Borderline Personality Disorder
- Interventions
- vafidemstat, Placebo
- Drug
- Lead sponsor
- Oryzon Genomics S.A.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Oceanside, California • Hialeah, Florida • Miami, Florida + 7 more
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
- Interventions
- SLC-391, pembrolizumab
- Drug · Biological
- Lead sponsor
- SignalChem Lifesciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
- Conditions
- Heart Failure, Caregiver
- Interventions
- HEROIC program, Active Comparator Control 1
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Baltimore, Maryland
- Conditions
- ARG1 Deficiency
- Interventions
- Loargys Arginine Test System
- Device
- Lead sponsor
- Immedica Pharma US Inc
- Industry
- Eligibility
- 0 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Copd, Smoking, Tobacco Use
- Interventions
- Bronchoscopy with Bronchoalveolar Lavage (BAL)
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2030
- U.S. locations
- 3
- States / cities
- San Francisco, California
- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 764198, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 20
- States / cities
- Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
- Conditions
- COPD
- Interventions
- biological/vaccine
- Biological
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 19 Years to 92 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- AP System (DiAs or inControl) with USS Virginia, Sensor-Augmented Pump Therapy (placebo)
- Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Stanford, California • Charlottesville, Virginia
- Conditions
- Pain
- Interventions
- JNJ-10450232 / Not yet marketed, acetaminophen / Tylenol
- Drug
- Lead sponsor
- McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- Testing of hepatic AAV Vector integration
- Diagnostic Test
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2040
- U.S. locations
- 15
- States / cities
- Rancho Cordova, California • Sacramento, California • San Francisco, California + 6 more
- Conditions
- Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Interventions
- ITIL-306
- Biological
- Lead sponsor
- Instil Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • New York, New York
- Conditions
- Liposarcoma, Dedifferentiated
- Interventions
- Brigimadlin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 21 more
- Conditions
- Interparental Conflict, Child Mental Health
- Interventions
- Family COMPASS, Families in Transition (FIT)
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 88 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Asthma
- Interventions
- GSK5784283
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
- Interventions
- TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Albumin-Bound Paclitaxel
- Drug
- Lead sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more